SILVER SPRING, Md.,
Oct. 9, 2013 /PRNewswire/ --
Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen")
announces the hiring of Confidence Ekeanyanwu as a Quality Control
Manager for its laboratory division. Ms. Ekeanyanwu will lead
Pharmagen's efforts to become cGMP complaint ahead of its' Food and
Drug Administration (FDA) registration and the pending federal
compounding legislation in Congress. She will be responsible for
aspects of USP/cGMP compliance, environmental monitoring and
quality systems. Confidence comes to Pharmagen from NBTY, Inc.
where she was a Micro Biologist II. Previously, she served
similar roles at both Teva Pharmaceuticals and PepsiCo.
Mackie Barch, Chief Executive
Officer of Pharmagen, commented that "we are very fortunate to find
Confidence, as she brings a broad array of quality control
experience from both the pharmaceutical and consumer goods
industries. She will enable us to strengthen our compliance
in an effort to continually exceed both UPS and cGMP
requirements. This is just another example of how Pharmagen
continues to demonstrate that we put patient safety
first."
About Pharmagen
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and
operating divisions Pharmagen Laboratories, Inc., Pharmagen
Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader
in innovative solutions to the nations sterile pharmaceutical
crisis. With a multifaceted approach, Pharmagen is meeting the
demand of health provider market through dynamic, independent
wholesale, compounding, and innovative IT solutions.
Nationally focused, Pharmagen is a dynamic distributor of specialty
drugs, compounding and admix pharmacy and producer of
over-the-counter ("OTC") branded multivitamins to the healthcare
provider market. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are
hard-to-find due to drug manufacturers' production shortages.
Contact: 888-264-4597 or info@pharmagenrx.com
Follow Us on Twitter: @pharmagenrx
Safe Harbor Statement
Information in this document
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "forecast", "anticipate", "estimate", "project",
"intend", "expect", "should", "believe", and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements involve, and are subject to known and
unknown risks, uncertainties and other factors which could cause
Pharmagen actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Pharmagen' filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Pharmagen herein are expressly qualified
in their entirety by the above-mentioned cautionary statement.
Pharmagen disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
SOURCE Pharmagen, Inc.